The chair of this ASX All Ords company just sold $6.5 million of shares. What gives?

Here's why this ASX All Ords company chair sold off a portion of his holdings…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points
  • Rhythm shares are edging higher by 1.85% to $1.375 during late morning trade
  • The company's executive chair Otto Buttula offloaded $6.5 million worth of shares to a domestic institutional fund manager
  • The primary purpose of the sale is to enhance portfolio diversification and better meet trustee, accounting, and auditor advice

The Rhythm Biosciences Ltd (ASX: RHY) share price is in the green during morning trade on Friday. This comes after the ASX All Ords company announced that its executive chair has just offloaded $6.5 million worth of his shares.

At the time of writing, the medical device company's shares are trading at $1.375, up 1.85%.

busy trader on the phone in front of board depicting asx share price risers and fallers

Image source: Getty Images

Rhythm chair sells down his stake

Investors are shrugging off the company's latest news, sending the Rhythm share price higher today.

According to Rhythm's release, its executive chair Otto Buttula offloaded $6.5 million worth of shares to a domestic institutional fund manager.

While the buyer's name wasn't disclosed, the on-market transaction involved 5,000 Rhythm shares sold at $1.30 apiece.

The exclusive share sale came from the Newfound superannuation fund in which Buttula is one of three members.

Rhythm stated that the primary purpose of the sale is to enhance portfolio diversification and better meet trustee, accounting, and auditor advice.

Prior to the sale, the superannuation fund's holding in Rhythm represented 95.9% of the total assets of the fund and 98.6% of its ASX listed company exposures.

However, now with the sale completed, the superannuation fund holds roughly 6.1 million Rhythm shares and about 2.1 million options at $1.80 each, expiring July 2024.

This is the first time Buttula has reduced his holdings in the ASX All Ords company since his appointment as chair in October 2019.

He also confirmed there is no intention to sell any further shares for the foreseeable future.

What did the chair of this ASX All Ords company say?

Commenting on the sale, Buttula said:

Whilst there is never a perfect time to reduce exposure to a company that you are immensely proud of being a part of, in this case, the numbers speak for themselves and a holding above 95% in one company exposure, particularly in a retirement fund, with two other members, was problematic and not prudent.

Despite the sale, my associated interests continue to maintain the largest shareholding in the company, maintaining a holding of 10.8% (ex-options). Importantly, I am also delighted to welcome another leading fund manager to the RHY register. The institutional fund manager is one of Australia's most successful and has conducted a period of due diligence on the prospects of the company.

Rhythm share price snapshot

Over the past 12 months, the Rhythm share price has gained 37% but fallen 11% year-to-date.

The company's shares reached a 2022 low of $1.01 in June before climbing in the weeks thereafter.

At today's prices, this ASX All Ords share has a market capitalisation of approximately $292.24 million with around 215.67 million shares on issue.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

A cool white-bearded man holds his hand up signalling you should halt.
Healthcare Shares

ASX 300 cannabis stock Incannex suspended ahead of 'material update'

The Incannex share price is frozen at 14 cents for now.

Read more »

a doctor in a white coat makes a heart shape with his hands and holds it over his chest where his heart is placed.
Healthcare Shares

Guess which ASX All Ords stock is rocketing 27% on a new FDA approval

Rett Syndrome has finally got an approved treatment.

Read more »

Five healthcare workers standing together and smiling.
Healthcare Shares

Buy these excellent ASX 200 healthcare shares: Goldman Sachs

Goldman has spoken very positively about these healthcare shares this week.

Read more »

medical asx share price represented by doctor giving thumbs up
Healthcare Shares

Guess which ASX biotech stock just rocketed 29% on big FDA news

The ASX healthcare share is attracting investor interest following FDA approval for its targeted cancer therapy compound.

Read more »

A doctor in a white coat sits at her computer with finger on mouth thinking about something in her office with medical equipment in the background.
Healthcare Shares

Should I buy CSL shares while they're under $300?

Can investors make a healthy return with this biotech?

Read more »

A man wearing a white coat holds his hands up and mouth open with joy.
Healthcare Shares

Mesoblast share price rockets 23% on FDA news

Mesoblast has received some good news for the US FDA this morning.

Read more »

A young woman wearing a blue blouse with white polkadots holds her phone up with an intrigued and happy look on her face as she reads some news.
Healthcare Shares

Owners of this ASX 200 share are soon going to receive a bigger dividend

Investors in this healthcare company are about to get a healthy cash boost.

Read more »

an older couple look happy as they sit at a laptop computer in their home.
Healthcare Shares

Hoping to collect the latest CSL dividend? Here's how

The next CSL dividend is fast approaching.

Read more »